HIMS Stock Analysis: Hims Hers Health | NYSE
Drug Manufacturers - Specialty & Generic | NYSE, USA | Market Cap: 7.214m USD | 12M Return: -43.6% | US4330001060 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 299M
EPS Trend: 57.6%
Qual. Beats: 0
Rev. Trend: 98.6%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Hims & Hers Health, Inc. (HIMS) is a consumer-focused digital health and wellness platform that connects customers with licensed healthcare professionals across multiple countries, including the United States, the United Kingdom, Canada, Germany, and Australia. The company sells prescription and non-prescription products through its websites and mobile app under the Hims & Hers brand, with offerings spanning general wellness, skincare, sexual health, hair care, and laboratory testing services. It also provides medical consultations, post-consultation support, and treatments for chronic conditions related to hormone health, weight loss, dermatology, and mental health, distributing through retail partnerships, physical stores, and online channels.
The company operates within the telehealth and direct-to-consumer (DTC) healthcare services sector, a sub-industry characterized by subscription-based and digital-first delivery models that bypass traditional brick-and-mortar pharmacy and clinic settings. Founded in 2017 and headquartered in San Francisco, the company was originally named Hims, Inc. before rebranding to Hims & Hers Health, Inc. in January 2021.
- GLP-1 weight loss drug demand drives subscriber growth
- International expansion in UK and Europe accelerates revenue diversification
- Competition from telehealth rivals pressures customer acquisition costs
| Net Income: -142.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -3.89 > 1.0 |
| NWC/Revenue: -3.83% < 20% (prev 53.80%; Δ -57.63% < -1%) |
| CFO/TA 0.07 > 3% & CFO 266.8m > Net Income -142.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 0.93 > 1.5 & < 3 |
| Outstanding Shares: last quarter (231.7m) vs 12m ago -9.75% < -2% |
| Gross Margin: 64.68% > 18% (prev 76.20%; Δ -11.52% > 0.5%) |
| Asset Turnover: 93.64% > 50% (prev 107.2%; Δ -13.60% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: -0.03 (Total Current Assets 1.38b - Total Current Liabilities 1.48b) / Total Assets 3.63b |
| B: -0.08 (Retained Earnings -292.2m / Total Assets 3.63b) |
| C: -0.06 (EBIT TTM -163.6m / Avg Total Assets 2.75b) |
| D: 0.10 (Book Value of Equity 324.1m / Total Liabilities 3.30b) |
| Altman-Z'' = -0.74 = B |
| DSRI: 3.0 (Receivables 375.3m/6.74m, Revenue 2.58b/2.01b) |
| GMI: 1.18 (GM 76.20% / 64.68%) |
| AQI: 3.62 (AQ_t 0.47 / AQ_t-1 0.13) |
| SGI: 1.28 (Revenue 2.58b / 2.01b) |
| TATA: -0.11 (NI -142.0m - CFO 266.8m) / TA 3.63b) |
| Beneish M = 0.53 (Cap -4..+1) = D |
As of October 18, 2026, the stock is trading at USD 28.07 with a total of 10,979,305 shares traded. Over the past week, the price has changed by -9.22%, over one month by +0.65%, over three months by -14.52% and over the past year by -43.61%.
Current recommended Stop Loss: 25.10 (which is 10.6% or 1.6 ATR below the current price).
Hims Hers Health has received a consensus analysts rating of 3.20. Therefore, it is recommended to hold HIMS.
- StrongBuy: 1
- Buy: 2
- Hold: 11
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 31.2 | 11% |
P/E Forward = 73.5294
P/S = 2.7982
P/B = 20.4392
P/EG = 2.5883
Revenue TTM = 2.58b USD
EBIT TTM = -163.6m USD
EBITDA TTM = -76.4m USD
Long Term Debt = 1.37b USD (from longTermDebt, last quarter)
Short Term Debt = 11.6m USD (from shortTermDebt, last quarter)
Debt = 1.73b USD (from shortLongTermDebtTotal, last quarter) + Leases 180.9m
Net Debt = 886.1m USD (calculated: Debt 1.73b - CCE 841.0m)
Enterprise Value = 8.10b USD (7.21b + Debt 1.73b - CCE 841.0m)
Interest Coverage Ratio = unknown (Ebit TTM -163.6m / Interest Expense TTM 0.0)
EV/FCF = 90.12x (Enterprise Value 8.10b / FCF TTM 89.9m)
FCF Yield = 1.11% (FCF TTM 89.9m / Enterprise Value 8.10b)
FCF Margin = 3.49% (FCF TTM 89.9m / Revenue TTM 2.58b)
Net Margin = -5.51% (Net Income TTM -142.0m / Revenue TTM 2.58b)
Gross Margin = 64.68% ((Revenue TTM 2.58b - Cost of Revenue TTM 910.5m) / Revenue TTM)
Gross Margin QoQ = 63.83% (prev 49.38%)
Tobins Q-Ratio = 2.23 (Enterprise Value 8.10b / Total Assets 3.63b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.73b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -129.3m (EBIT -163.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.93 (Total Current Assets 1.38b / Total Current Liabilities 1.48b)
Debt / Equity = 5.33 (Debt 1.73b / totalStockholderEquity, last quarter 324.1m)
Debt / EBITDA = -11.60 (negative EBITDA) (Net Debt 886.1m / EBITDA -76.4m)
Debt / FCF = 9.86 (Net Debt 886.1m / FCF TTM 89.9m)
Total Stockholder Equity = 473.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.16% (Net Income -142.0m / Total Assets 3.63b)
RoE = -30.03% (Net Income TTM -142.0m / Total Stockholder Equity 473.0m)
RoCE = -8.90% (EBIT -163.6m / Capital Employed (Equity 473.0m + L.T.Debt 1.37b))
RoIC = -6.37% (negative operating profit) (NOPAT -129.3m / Invested Capital 2.03b)
WACC = 13.98% (E(7.21b)/V(8.94b) * Re(17.33%) + D(1.73b)/V(8.94b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 17.33% (= CAPM, Blume Beta Adj.) -> capped to 12.54%
Shares (quarterly) Correlation: 14.39 | Cagr: 0.46%
[DCF] Terminal Value 55.17% ; FCFF base≈101.7m ; Y1≈89.2m ; Y5≈72.1m
[DCF] Fair Price = N/A (negative equity: EV 606.2m - Net Debt 886.1m = -280.0m; debt exceeds intrinsic value)
EPS Correlation: 57.62 | EPS CAGR: 74.47% | SUE: -0.18 | # QB: 0
Revenue Correlation: 98.56 | Revenue CAGR: 59.80% | SUE: 1.27 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.06 | Chg30d=-6.79% | Revisions=-40% | Analysts=11
EPS current Year (2026-12-31): EPS=-0.56 | Chg30d=-2.47% | Revisions=-40% | GrowthEPS=-209.9% | GrowthRev=+36.6%
EPS next Year (2027-12-31): EPS=0.42 | Chg30d=-4.01% | Revisions=+0% | GrowthEPS=+174.8% | GrowthRev=+24.6%
[Analyst] Revisions Ratio: -44% (up=1, down=5)